Por ejemplo, a las 40 semanas de tratamiento, los pacientes tratados con retatrutida mostraron una mayor reduccin de HbA1c y peso que aquellos que recibieron placebo
We also highlighted the latest product ratings updates from our labs
Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases
Known Hypersensitivity Ensuring that youre not known to be hypersensitive to retatrutide or its ingredients is a must before starting treatment
Unlike earlier-generation weight-management agents, retatrutide is a triple receptor agonist , meaning it simultaneously activates three distinct hormonal receptors: GLP-1 (glucagon-like peptide-1) receptor promotes insulin secretion, reduces appetite, and slows gastric emptying [9] [10] GIP (glucose-dependent insulinotropic polypeptide) receptor enhances insulin release and may improve fat metabolism [12] [13] Glucagon receptor increases energy expenditure and may reduce hepatic steatosis, as suggested by imaging data (MRI-PDFF) from Phase 2 trials, though this effect requires confirmation in larger studies [2] [5] This triple-agonist mechanism distinguishes retatrutide from agents such as semaglutide (GLP-1 only) or tirzepatide (GLP-1/GIP dual agonist), and is thought to produce more pronounced reductions in body weight and improvements in metabolic parameters
However, if better includes current clinical availability, proven long-term safety data, and a lower impact on resting heart rate, Tirzepatide remains the gold standard of the present day
